Company intelligence / Profile preview

CEAMED

Ownership: Private
Development stage: Other

Overview

CEAMED develops small molecule inhibitors targeting STAT3 for oncology applications. Their lead compound CM‑978 shows potent inhibition of IL‑6 activated STAT3 with promising pharmacokinetics and low toxicity in animal models. The company has proposed its compounds as candidates for both triple negative breast cancer and as potential treatments to mitigate the cytokine storm associated with COVID‑19

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CM-978

Preclinical

Partnerships

Seeking collaborators/partners for further development

Beyond the preview

Go deeper on CEAMED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEAMED.

Explore the full profile